JP MORGAN/CALL/VERTEX PHARMACEUTICALS/460/0.1/17.01.25 | Real-time Bid/Ask 09:43:01 2024-07-17 am EDT | ||
| 6.22 EUR / 6.3 EUR | -3.99% |
|
| Current month | +24.67% | ||
| 1 month | +16.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 5.93 | -9.05% |
| 24-07-16 | 6.52 | +4.32% |
| 24-07-15 | 6.25 | -1.73% |
| 24-07-12 | 6.36 | +0.95% |
| 24-07-11 | 6.3 | +6.78% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 04:49 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB95ZA |
| ISIN | DE000JB95ZA1 |
| Date issued | 2023-12-21 |
| Strike | 460 $ |
| Maturity | 2025-01-17 (184 Days) |
| Parity | 10 : 1 |
| Emission price | 3.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.52 € |
|---|---|
| Lowest since issue | 2.21 € |
| Spread | 0.2 € |
| Spread % | 3.25% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
489
USD
Average target price
473.5
USD
Spread / Average Target
-3.17%
- Stock Market
- Warrants
- Warrant
